FDA
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
-
-
-
-
-
-
-
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Trial
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
-
-
-
-
-
-
-
Amylyx Pharmaceuticals (AMLX) Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
-
325,450 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

